Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Seattle Genetics and Bayer HealthCare will collaborate on developing new antibody-drug conjugates (ADCs). Bayer is paying up-front and option exercise fees of up to $20 million for rights to use Seattle Genetics’ auristatin-based ADC technology for several oncology targets. Seattle Genetics could also receive up to $500 million in milestone payments. Through such strategic alliances, Seattle Genetics could receive more than $3.5 billion in milestone payments. More than 15 ADCs using its technology are in clinical development.
This article has been sent to the following recipient: